At Biopôle since 2010.

Xigen is developing innovative therapeutic peptides for a broad range of diseases with underserved medical needs and proven commercial value, with a focus on inflammation.

Xigen’s technology platform enables the design and synthesis of cell-penetrating peptides with enhanced metabolic stability, using proprietary carrier motifs to selectively deliver them to intracellular targets.